Metabolon Platform Powers Largest Metabolomic Study in CAR-T Therapy, Uncovering Neurotoxicity Insights

Metabolon, a global leader in metabolomics, announced that its metabolomics platform enabled what the company describes as the largest metabolomic analysis to date in CAR-T cell therapy, generating new insights into severe neurotoxicity associated with the treatment. The study analyzed metabolic profiles from patients undergoing CAR-T therapy and identified distinct metabolite patterns correlated with immune effector cell-associated neurotoxicity syndrome (ICANS), a potentially life-threatening complication. Researchers were able to identify clear, reproducible metabolic signatures that classified patients who developed high-grade NEs using metabolomics to reveal mechanisms that are invisible to genomic, proteomic and cellular assays.

CAR-T therapies have transformed treatment for certain hematologic cancers, but serious side effects such as cytokine release syndrome and neurotoxicity remain significant clinical challenges. By applying high-throughput metabolomics to CAR-T patients, Metabolon’s platform supports more detailed biomarker discovery efforts. For oncology researchers and biopharma developers, the findings underscore how multi-omics approaches are becoming central to managing risk and refining next-generation cell therapies.

Posted by MedCloudInsider Editors on 02/18/2026